Arm Holdings American Depositary SharesNASDAQ: ARM

A couple of years ago, many American investors probably had never heard of British chip designer Arm (NASDAQ: ARM ), which has become a Wall Street darling on the artificial intelligence hardware trend. Ignore the temptation to jump in now; it's too late as ARM stock is grossly overvalued.

Arm Holdings has a significant opportunity as Neoverse is adopted across the hyperscalers to bolster data retrieval with lower power requirements. ARM anticipates significant growth opportunities beyond smartphone market with ARMv9 adoption with more content/chip and CSS chips. ARM CPU + Nvidia GPU may navigate hyperscalers away from the x86 for CPU, allowing for ARM to take on new market share.

Semiconductor stocks Nvidia and Arm led the Nasdaq-100 higher during the first half of 2024, but Wall Street is less optimistic about their prospects in the second half. Nvidia is the market leader in data center GPUs and AI chips, and the company has burgeoning side businesses in CPUs, networking equipment, and software.

The semiconductor industry is the bedrock of the digital age. Semiconductors have provided the essential building blocks for computers, smartphones, and countless other electronic devices that power our modern world.

There's more to the current rally in technology stocks than Nvidia (NASDAQ: NVDA ). Nvidia stock continues to get the lion's share of attention from the financial press.

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with the anti-PD-1 immune-checkpoint inhibitor. Figure 1 To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/8000/214171_cc2e2f8084a9e943_002full.jpg Using Defence's Accum® platform, the Company previously demonstrated that AccuTOX® treatment of MSCs results in the induction of antigen cross-presentation capacity (ARM-X cells), which can mount potent anti-tumoral responses in animal pre-clinical models.

Rene Haas, Arm Holdings CEO, joins 'Closing Bell Overtime' to talk performance since IPO, AI partnerships, smartphone demand and more.

Arm's lucrative royalty-based business benefits from the exploding demand for energy-efficient chips. Data centers need lots of memory capacity for AI to work properly, and that favors Micron Technology.

As ARM Holdings NASDAQ: ARM continues its impressive climb, market participants, be they investors, traders, or speculators, increasingly wonder if the stock's rapid rise is sustainable or has surged too quickly.